Background-The purpose of this analysis was to examine whether implantable hemodynamic monitor-derived baseline estimated pulmonary artery diastolic pressure (ePAD) and change from baseline ePAD were independent predictors of all-cause mortality in patients with chronic heart failure. Methods and Results-Retrospective analysis used data from 3 studies (n=790 patients; 216 deaths). Baseline ePAD was related to mortality using a multivariable model including baseline and demographic data. Changes in ePAD defined as change from baseline to 6 months and from baseline to 14 days before death or exit from study were related to subsequent mortality, and analysis was adjusted for baseline ePAD. Area under the pressure versus time curve during 180 days before death or exit from study was related to mortality. Baseline ePAD, independent of other covariates, was a significant predictor of mortality (hazard ratio=1.07; 95% confidence interval=1.05-1.09; P<0.0001). Change in ePAD was an independent predictor of mortality (hazard ratio=1.07; 95% confidence interval=1.05-1.100; P=0.0008). Increased ePAD of 3, 4, or 5 mm Hg from baseline to 6 months was associated with increased mortality risk of 23.8%, 32.9%, or 42.8%. Change in ePAD from baseline to 14 days before death or exit from study was higher in patients who died (3.0±8 versus 1.7±10 mm Hg; P=0.003). Area under the pressure versus time curve in the final 180 days before death or exit from study was higher in patients who died versus those alive at end of study (185±668 versus 17±482 mm Hg.days; P=0.006). Conclusions-Implantable hemodynamic monitor-derived baseline ePAD and change from baseline ePAD were independent predictors of mortality in chronic heart failure patients. (Circ Heart Fail. 2017;10:e003594.
D
ata from previously published studies suggest that management strategies to treat patients with chronic heart failure (CHF) might be facilitated by knowledge of cardiac pressure data obtained from an implantable hemodynamic monitor (IHM). [1] [2] [3] [4] Baseline pressure at the time of implantation, change from baseline to 6 months after implantation, and the product of pressure versus time have been shown to be significant predictors of heart failure hospitalizations (HFHs). [1] [2] [3] [4] The use of IHM-pressure-guided care has been demonstrated to decrease filling pressures and reduce the rate of HFHs. [1] [2] [3] [4] However, whether there is a significant relationship between IHM-derived pressures and all-cause mortality rate is unknown. Furthermore, studies suggest that there is a direct relationship between the number of HFH and subsequent mortality rate [5] [6] [7] [8] [9] [10] ; therefore, it seems reasonable to postulate that because lower IHM-derived pressures are associated with a lower rate of HFHs in CHF patients, there should also be an association between IHM-derived pressures and mortality rate. However, none of the previous studies using IHM have been powered to sufficient size or sufficient follow-up duration to define a relationship between IHM-derived pressures and mortality rate. [1] [2] [3] [4] [11] [12] [13] [14] Accordingly, data from CHF patients who have undergone implantation of an IHM with the Medtronic Chronicle devices were examined over the life span of the device follow-up. IHM-derived pressure data, along with many other demographic variables that may have predictive value for mortality in patients with CHF, were analyzed in an effort to (1) examine whether baseline estimated pulmonary artery diastolic pressure (ePAD) was an independent predictor of mortality rate and (2) examine whether there Intracardiac Pressures and Mortality was a relationship between a change in ePAD from baseline and subsequent mortality rate.
Methods

Patient Population
A retrospective analysis of existing patient data collected from 3 studies: Chronicle Phase II, COMPASS-HF (Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure), and REDUCE-HF (Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure trial) was performed. [11] [12] [13] [14] The data presented are from 790 CHF patients who had undergone implantation of an IHM; data were collected over the life span of the device or until the patient died. There was a mean follow-up of 2.9±2.2 years (range: 0.1-12.5 years). Detailed description of study designs have been previously published. [11] [12] [13] [14] In brief, the Chronicle Phase II study used a multicenter, prospective, nonrandomized design. The primary intention of the Chronicle Phase II was to assess the safety of the device and to gain insights into the clinically relevant information obtained from the IHM. Chronicle Phase II included 116 patients but did not include laboratory values. COMPASS-HF and REDUCE-HF were prospective, multicenter, randomized, single blinded, parallel controlled trials. COMPASS-HF evaluated data from 274 New York Heart Association III or IV CHF patients who received a Chronicle IHM; the patients were randomized to IHM-facilitated care (Chronicle group, n=134) or to standard treatment (control group, n=140). Both groups had hemodynamic information recorded; however, the hemodynamic information was used to guide management only in the Chronicle group until the randomized follow-up period was completed. REDUCE-HF included data from 400 CHF patients (New York Heart Association II and III) implanted with an IHM combined with an implantable cardiac defibrillator (ICD) and were randomized to the Chronicle or control groups. As described above in the COMPASS-HF trial, both groups in REDUCE-HF had hemodynamic information recorded; however, the hemodynamic information was only used in the management of the Chronicle group during the randomized period.
The study was approved by the ethics committees at each participating institution and all patients gave written informed consent.
Device Description
The Chronicle IHM continuously measured and stored right ventricular systolic pressure, right ventricular diastolic pressure, and the ePAD, maximum positive and negative changes in pressure over time, heart rate, and activity. ePAD was assessed as the pressure in the right ventricle at the time of pulmonary valve opening, which occurs at the time of maximum+dP/dt. [14] [15] [16] In the absence of significant pulmonary vascular disease (defined as the subjects with severe COPD or severe restrictive airway disease [forced expiratory volume in 1 second 1 ≤1 L or ≤50% predicted] or primary pulmonary hypertension), which was an exclusion criterion for all 3 studies, ePAD provided a clinical estimate of pulmonary artery diastolic pressure. Daily median ePAD values were calculated and recorded. The system components, implantation procedure, monitoring process, storage and retrieval methods, and pressure analysis methods have previously been described.
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Statistical Analysis
The purpose of this analysis was to examine whether baseline ePAD, as well as change in ePAD from baseline, were independent predictors of mortality. Baseline ePAD was defined as the mean of the daily median values averaged over days 0 to 14 after IHM implantation with day 0 being day of implantation (Figure 1 ). Over a 24-hour time period, the ePAD values were not normally distributed; therefore, daily values were calculated as medians. By contrast, the daily medians over 0 to 14 days were normally distributed; therefore, baseline ePAD was calculated as the average of the median values over 0 to 14 days. For completeness, baseline ePAD is presented as mean±SD and as median as shown in Table 1 . Change in ePAD was evaluated using 3 time frames: (1) change in ePAD from baseline to 6 months (6 months defined as the mean of the daily median averaged from days 169 to 183 after IHM implantation); (2) change in ePAD from baseline to 14 days before the patient died or exited the study (ie, patient withdrew from study, the chronicle device reached end of device life and was not replaced, or study was closed to follow-up), and (3) change in the area under the ePAD versus time curve (AUC) during the 6 months before death or exit from study ( Figure 1) .
The baseline demographics were compared between the 3 studies using an ANOVA for continuous variables and a Fisher exact test for categorical variables; laboratory values, however, were not reported in Chronicle phase II and could not be compared. A Cox proportional hazards regression model was used to estimate the association between baseline variables (including ePAD) and mortality. Each baseline variable (Table 1 ) was examined in univariate analyses. All significant covariates (P<0.05) identified from the univariate analyses were then included in the baseline multivariable Cox regression model. To further account for differences in trial design, trial populations, and advances in guideline-directed medical and device therapy during the course of 3 studies that are not explained by the variables collected in the 3 studies, 2 additional covariates were included in the Cox multivariable model: indicator for which study the subject was enrolled and a covariate indicating the year the subject was enrolled in the trial. To assess for any nonlinearity, the relationship between baseline ePAD and mortality was modeled with a smoothing spline using penalized splines (P-splines). 17 The relationship between change in ePAD (from baseline to 6 months) and mortality was evaluated using 2 different analyses: continuous and partition; each used a landmark analysis from 6 months after implantation of IHM to end of study (study exit or death, average length of study follow-up was 2.9 years). A total of 128 patients were excluded from the landmark analysis, 45 in the phase II study, 32 in COMPASS-HF, and 51 in REDUCE-HF. The relationship between change in ePAD from baseline to 6 months and mortality was evaluated. A Cox regression model was used, with change in ePAD from baseline to 6 months and baseline ePAD as continuous covariates in the model and mortality after 6 months as the dependent variable. Significant baseline variables were also included as covariates in the change in ePAD model, so that the landmark analysis accounted for the same baseline variables as the baseline ePAD multivariable model. Similarly, study indicator and enrollment year were also included as covariates to account for differences in trial design, trial populations, and advances in guideline-directed medical and device therapy during the course of 3 studies that are not explained by the variables that were collected in the 3 studies. Estimates of risk associated with selected partition values based on a change in ePAD of 3, 4, 5, or 6 mm Hg from baseline ePAD were calculated from the Cox model. These partition values were chosen because the average change in ePAD from compensated to decompensated heart failure was ≈ 4 mm Hg. 3 In addition, to support the finding from the Cox models above, Kaplan-Meier survival curves were created for the categorical analyses described below. The proportional hazards assumption was assessed using the methods of Lin et al. 18 The relationship between change in ePAD from baseline and mortality was examined using 2 additional methods: change in ePAD from baseline to last 14 days before death or exit and change in ePAD in the 6 months before death or exit from the study using an AUC analysis. Changes in ePAD from baseline to the last 14 days are summarized as mean±SD. An ANCOVA model was used to compare patients who died versus those who exited the study at the end of the study. Baseline ePAD was included in the ANCOVA model to account for baseline ePAD. Baseline for the AUC was defined as the average daily ePAD values on days −194 to −180 before death or exit for each subject. The pressure difference for each day minus the baseline was calculated for all days from −179 to −1 days before death/exit. The AUC was calculated using the summation of each daily pressure difference across all days −180 to −1 (AUC sum). In the event that a patient did not have data every day during that time period, the AUC sum was normalized in order for each subject to have the equivalent of 180 days of data. Subjects were included in this analysis based on the following: at least 7 days of reported ePAD between days −194 and −180 (baseline AUC calculation), the baseline AUC ePAD must be >10 mm Hg, at least 50 days of reported ePAD between days −179 and −1 days before exit/death, and finally, each subject must have died or exited the study a minimum of 195 days from implant. A total of 487 subjects were included in this analysis. AUC was presented as mean±SD. An ANCOVA model was used to compare AUC of ePAD in patients who died and patients who exited the study after reaching end of follow-up. Baseline ePAD for the AUC was included in the ANCOVA model to account for the baseline ePAD pressure.
All analyses were conducted using SAS software, version 9.4 (SAS institute) or R (www.r-project.org). 
Results
Demographics and Study Population
There were significant differences in baseline demographics between patients enrolled in Chronicle-II versus COMPASS-HF versus REDUCE-HF (Table 1) . However, taken together, these 3 studies enrolled patients across the spectrum of CHF and had typical demographic characteristics for a CHF population. A total of 216 deaths occurred; 45 in the Chronicle Phase II study (39%), 124 in the COMPASS-HF study (45%), and 47 in the REDUCE-HF study (12%). The average follow-up was 2.9±2.2 years. The average mortality rate for Chronicle Phase II was 11.1% per patient-year, COMPASS-HF was 14.5% per patient-year, and REDUCE-HF was 4.5% per patient-year.
Relationship Between Baseline ePAD and Mortality
The relationship between baseline covariates and mortality was examined using a univariate analysis (Table I in the Data  Supplement) . Among these covariates, significant predictors of mortality included mean baseline ePAD; patients with a baseline ePAD value above the median (>23 mm Hg) had a significantly higher mortality rate than those with a baseline ePAD below the median (≤23 mm Hg; P<0.001; Figure 2 ). The strongest univariate predictors of mortality were left ventricular end diastolic diameter, age at time of implant, number of years with a diagnosis of CHF, number of HFHs in the 6 months before enrollment, and baseline ePAD. All of the significant covariates identified in the univariate model were then included in a multivariable model. Table  2 presents those covariates that remained significant in the multivariable model, after adjusting for all of the significant univariate covariates. These multivariable parameters associated with mortality are presented in order of significance (Table 2 ) and included 6-minute hall walk distance, body mass index, age, New York Heart Association class, left ventricular end diastolic diameter, and baseline ePAD. Baseline ePAD had the highest χ 2 value indicating the most significant variable that predicted mortality (hazard ratio, 1.07; 95% confidence interval=1.05-1.09; P<0.0001). The Figure 2 . Relationship between baseline estimated pulmonary artery diastolic pressure (ePAD) and mortality. When baseline ePAD was above the median value of 23 mm Hg, mortality was significantly greater than when baseline ePAD was ≤23 mm Hg (P<0.001, log-rank test). *Covariates that were included in the multivariable model but that were not significant in the multivariable model were as follows: ischemic cause of heart failure, presence of atrial fibrillation, diastolic blood pressure, heart failure hospitalizations in the 6 mo before enrollment, and number of years diagnosed with chronic heart failure. Intracardiac Pressures and Mortality relationship between mortality and baseline ePAD was also examined using a nonlinear Spline analysis (test for nonlinearity P=0.02; Figure 3) . Over a physiological range of ePAD (≈15-35 mm Hg), there was a linear relationship between baseline pressure and the probability of mortality, whereas at the extremes of ePAD, this relationship tended to plateau and have wider confidence intervals because of fewer samples.
Although not significant in the multivariable model, prognostic factors blood urea nitrogen and glomerular filtration rate were significant in the univariate analysis. Higher blood urea nitrogen was associated with an increase risk of mortality (hazard ratio=1.03; 95% confidence interval=1.05-1.089; P<0.0001), and higher glomerular filtration rate was associated with a decreased risk of mortality (hazard ratio=0.97; 95% confidence interval=0.96-0.98; P<0.0001).
Relationship Between Change in ePAD From Baseline to 6 Months and Mortality
Beyond 6-month follow-up, there were 662 patients and 162 deaths. In Chronicle Phase II (n=71 with 23 deaths), baseline ePAD=25±7 mm Hg and change in ePAD at 6 months=1±6 mm Hg (P=0.06). In COMPASS-HF (n=242 with 102 deaths), baseline ePAD=27±8 mm Hg and change in ePAD at 6 months=0±7 (P=0.62). In REDUCE-HF (n=349 with 37 deaths), baseline ePAD=21±6 mm Hg and change in ePAD at 6 months=1±6 mm Hg (P<0.01).
Examined as a continuous variable, there was a significant relationship between the change in ePAD from baseline to 6 months and mortality after adjusting for baseline pressure (hazard ratio=1.04 [95% confidence interval=1.01-1.06]; P=0.0008). Cox regression model estimates of a: 3, 4, 5 and 6 mm Hg increase in ePAD from baseline to 6 months was associated with an increase in risk of mortality of 23.8%, 32.9%, 42.8%, and 53.3%, respectively; a 3, 4, 5 and 6 mm Hg decrease in ePAD was associated with an decrease in risk of mortality of 19.2%, 24.8%, 30.0%, and 34.8%, respectively (Table 3 ; Figure 4 ). The number of patients who had these changes in ePAD are displayed on the x axis of Figure 4 . In aggregate, 29% of the patients (193/662) had an ePAD increased ≥3 mm Hg from baseline to month 6 and 18% of the patients (117/662) had an ePAD decreased ≥ 3 mm Hg from baseline to month 6.
Further analyses were performed to determine whether changes in ePAD beyond 6 months would remain predictive of subsequent mortality rate. Change in ePAD from baseline to 14 days before death or exit from study was higher in patients who died (3.0±8 versus 1.7±10 mm Hg; P=0.003; Table 3 ). The baseline pressure for the AUC analysis just before the start of the AUC analysis was higher in patients who subsequently died compared with those who exited (28.3±6.9 in those who died versus 23.3±6.6 mm Hg in those who exited). The AUC in the 6 months before death or exit from study was higher in the patients who died (185±668 versus 17±482 mm Hg.days; P=0.001, adjusted for baseline differences; Table 3 ); this change in AUC occurred in addition to the already increased baseline pressure at the start of the AUC calculation.
Discussion
The data presented in the current analysis using ePAD measured by the Chronicle IHM support the following conclusions. First, baseline ePAD is a predictor of mortality in patients with CHF, independent of other baseline covariates that have previously been demonstrated to predict mortality. Second, a change in ePAD, from baseline to 6 months alters subsequent mortality rate; this relationship between change in ePAD and subsequent mortality is durable.
Risk Models That Incorporate Direct or Indirect Measures of Intracardiac Pressures
A limited number of studies have examined either direct or indirect measures that reflect volume status and related these The relationship between probability of death during the study and baseline estimated pulmonary artery diastolic pressure (ePAD) was modeled using a smoothing spline (P-splines) with 4 degrees of freedom. Probability of death through 2.9 y is plotted in Figure 3 . Over a physiological range of ePAD (≈15-35 mm Hg), baseline pressure is directly related to probability of mortality. At the extremes of ePAD, this relationship tends to plateau. The vertical dashes on the x axis indicate baseline ePAD in individual patients.
measurements to mortality; however, there are no previously published studies that have examined the prognostic value of a change in pressure over time in an outpatient setting using a remote monitoring system to predict mortality in CHF patients. The CHAMPION study (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Class III Heart Failure Patients) used an IHM to test the safety and efficacy of adding knowledge of daily pulmonary artery pressures to management of patients with CHF. This study demonstrated that management informed by IHM-derived data reduced intracardiac pressures and reduced HFHs. 1 To date, no data about the relationship between baseline pressure mortality and change in pressure from baseline have been published from the CHAMPION study.
The relationship between mortality and baseline or change from baseline metrics using indirect measures of volume status Figure 4 . Relationship between change in estimated pulmonary artery diastolic pressure (ePAD) from baseline to 6 mo after implantation of the implantable hemodynamic monitor (IHM) and mortality using a partition value analysis. Cox regression model estimates of a 3, 4, 5 and 6 mm Hg increase in ePAD from baseline to 6 mo was associated with an increase in risk of mortality of 23.8%, 32.9%, 42.8%, and 53.3%, respectively. The number of patients with absolute ePAD changes from baseline to month 6 are presented on the x axis, displaying a large range of pressures that occurred during the study. 19, 20 A recent study demonstrated that directly measured intrathoracic impedance, measured using an implantable cardiac defibrillator or chronic resynchronization device, provided data that could be used to identify risk stratification in patients with heart failure with reduced ejection fraction. 21 Specifically, baseline-measured impedance predicted all-cause mortality. Changes from baseline-measured impedance resulted in a change in the predicted mortality. Thus, measured impedance also supported risk stratification in CHF patients.
Pathophysiologic Implications and Results of Diuretic Trials
The current and previous IHM study analyses indicate that achieving lower left ventricular diastolic filling pressures is associated with a lower morbidity and mortality. 1, [22] [23] [24] In these studies, the most common (but not only) medication alteration used was an adjustment in diuretic dose to reduce volume. 11, 25 This may appear contradictory when compared with both diuretic and ultrafiltration trial results in which an increased diuretic-induced or ultrafiltration-induced volume loss was not accompanied by an improvement in morbidity and mortality. [25] [26] [27] [28] [29] [30] [31] [32] [33] Several possible explanations may be relevant. First, serial, in fact daily, assessment of filling pressures was made only in the IHM studies. Second, the diuretic dose adjustment was fractionally smaller and more frequent in the IHM studies. Third, it is likely that a higher level of medication-induced sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) blockade was achieved in the IHM studies. It seems likely that these differences resulted in a much smaller daily extent of volume loss and a much slower total volume loss that could be tailored to the individual patient. This slower, smaller volume change would be less likely to cause further activation of the SNS and RAAS. Furthermore, knowledge of daily pressure (volume) status would facilitate a more successful attempt at achieving target doses of SNS and RAAS agent blockade. Many studies have shown that the intensity of RAAS/SNS activation is proportional to the rapidity and extent of volume redistribution. 34, 35 Intensified RAAS/SNS activation leads to increased volume avidity, rebound hypervolemia, and diuretic refractoriness. [34] [35] [36] [37] It seems likely that small, incremental, progressive volume adjustments could avoid RAAS/SNS activation and lead to lower filling pressures. It is just this strategy that the leadership committees advocated and investigators achieved in the CHAMPION, REDUCE-HF, and HOMEOSTASIS (Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients) studies (1, 12, (22) (23) (24) . In these studies, small daily changes in diuretics were combined with significant titration of nitrates, RAAS, and SNS antagonists. Both up and down titrations of diuretics were used to respond to changes in IHM pressures. By contrast, dose titration in diuretic and ultrafiltration studies predominantly judged adequacy of volume adjustment by following body weights, a measure shown to have a poor correlation with filling pressures and volume status. 38 ,39
Limitations
The current study used retrospective data in a post hoc analysis from studies performed 5 to 10 years ago. These data stimulate the hypothesis that management of patients with CHF that lowers baseline ePAD and maintains an appropriate ePAD during follow-up could reduce mortality; however, none of the data examined can be used to prove this hypothesis. To do so require additional prospective, randomized trials that examine the differences in mortality using data from IHMs to direct management versus patients treated with standard management. Even as guideline-directed therapy improves and continues to lower mortality rate, there is no reason to expect that these changes in medical therapy will change the relationship between changes in pressure and subsequent mortality.
In the current study, a multivariable model was used to predict mortality. This model included many (but not all) of the possible variables used in other mortality in CHF scores. [40] [41] [42] [43] Each of these scoring systems emphasized the use of a single baseline assessment of clinical/demographic variables, indices of structure and function, and standard laboratory evaluations; none incorporate direct measurements of intracardiac pressures and none incorporate repetitive measures during follow-up. Whether previous CHF scores can be adapted to a more dynamic application, examine change in risk, and be used to alter management of CHF over time is less certain.
One of the most recently validated predictors of mortality in CHF patients are biomarkers, particularly natriuretic peptides. No B-type Natriuretic Peptide or N-terminal pro B-type natriuretic peptide data were available in the current study. However, because natriuretic peptide levels parallel changes in LV diastolic wall stress, the major component of which is LV diastolic pressure, ePAD and NPs would be expected to be colinear. Whether change in ePAD would be additive to changes in NPs (or vice versa) has not been examined. The advantage of ePAD is the ability to provide remote and continuous measurements.
Conclusions
Baseline ePAD is a predictor of mortality, independent of other covariates that have previously been demonstrated to predict mortality. Change in ePAD, from baseline to 6 months was associated with changes in subsequent mortality rate; this relationship is durable.
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